Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EBITDA (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed EBITDA for 4 consecutive years, with -$219.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 257.97% year-over-year to -$219.0 million, compared with a TTM value of -$1.1 billion through Dec 2025, down 388.28%, and an annual FY2025 reading of -$1.1 billion, down 388.28% over the prior year.
  • EBITDA was -$219.0 million for Q4 2025 at Summit Therapeutics, up from -$231.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$15.8 million in Q2 2023 and bottomed at -$565.9 million in Q2 2025.
  • Average EBITDA over 4 years is -$139.4 million, with a median of -$58.2 million recorded in 2024.
  • The sharpest move saw EBITDA skyrocketed 91.98% in 2024, then crashed 837.92% in 2025.
  • Year by year, EBITDA stood at -$17.9 million in 2022, then plummeted by 104.93% to -$36.7 million in 2023, then tumbled by 66.74% to -$61.2 million in 2024, then crashed by 257.97% to -$219.0 million in 2025.
  • Business Quant data shows EBITDA for SMMT at -$219.0 million in Q4 2025, -$231.8 million in Q3 2025, and -$565.9 million in Q2 2025.